Skip to NavigationSkip to content

Business Services

Novo Holdings invests £53.5 million into Oxford Biomedica

Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million.

Novo will buy 6.6 million new shares at a price of £6.90 each paying a total of £45.5 million. The Novo Nordisk owned holding company will then buy a further 1.2 million shares at the same price.

The price Novo will pay is equivalent to the market closing price on 24 May 2019. The investment comes as the British firm’s gross income increased by 72% last year.

Living with Scimitar syndrome

Published on 28/05/19 at 11:44am

Katy Baker has lived her entire life with the rare congenital heart defect Scimitar syndrome. She reflects on the system that treated her, how she has learned to live with the disease, and why it spurred her to advocate for patients like herself.

What is Scimitar syndrome?

It affects one in 100,000 people. It’s a congenital heart defect, which means that the blood from the pulmonary valve doesn’t drain into the right lung, so only the left lung works. So, it’s a heart defect, but only one of your lungs work as well.

Top Ten most popular articles on this week

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week's biggest stories in the pharmaceutical industry.

Drugmakers colluded to drive up price of anti-nausea drug by 700%

Four pharmaceutical firms have been accused of illegally colluding to restrict the supply of anti-nausea medication Prochlorperazine after the price of the drug increased by 700%.

The price of Prochlorperazine increased from £6.49 per pack to £51.68, between 2013 and 2018, after four drugmakers agreed not to compete.

Japan's health ministry warns of serious side effects of Lilly's Verzenio

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs.

The health ministry said Verzenio is suspected of adversely affecting patients’ lungs after 14 patients developed a serious lung disease and three died.

The drug has been blamed for at least four of the 14 cases of lung disease, one of which resulted in death.

The global rise in antibiotic resistance threatens infection prevention and cure

Published on 20/05/19 at 01:23pm

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic stewardship required to offset this global threat, and the additional incentivisation initiatives needed to promote innovation, as well as the role of preventative antimicrobial treatments as an important element of this global fight against AMR.

Top Ten most popular articles on this week!

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate lawsuits accused them and others of suppressing competition. While Gilead had sought to retain dominance in the HIV drugs market, Teva was alleged to be at the centre of a conspiracy through which generic drugmakers divided up the market for generic meds.

A day in the life: Lance Hill, CEO at Within3

Published on 17/05/19 at 09:23am

Could you give a short history of how you came to be in your current role?

I've spent my entire career in technology.  My passion is how technology is applied to change the way we work and live.  When social media technologies emerged, I became very interested in how this new technology paradigm would change the workplace.  That led to Within3, where we focus on improving communication throughout all the stakeholder groups within healthcare. 

Insider Interview: Paving paths in prostate cancer

Published on 16/05/19 at 11:39am

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses Janssen’s vision in Oncology and how the company is building on its heritage in prostate cancer to deliver transformational outcomes for patient.

What is Janssen’s vision in oncology?

ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 trial of its ovarian cancer drug mirvetuximab soravtansine.

The experimental antibody-drug conjugate (ADC) mirvetuximab soravtansine is being trialled in patients with high folate receptor (FR) alpha-positive, platinum-resistant ovarian cancer.

In March, Massachusetts-based biotech ImmunoGen reported that its 366 patient FORWARD I trial had failed to meet its primary endpoint of progression free survival.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches